Skip to main content

$0.315 0.010 (3.28%)

High

$0.32

Low

$0.30

Trades

243

Turnover

$627,825

Volume

2,012,212
30 June 2023 at 4:10pm
Register to track IMM and receive email alerts.
Subject
IMM Ann: New investigator-initiated ph2 trial in Soft Tissue Sarcoma

IMM Ann: Appendix 4E & 2022 Full Year Statutory Accounts

IMM Ann: Japanese Patent Grant for efti, soluble LAG-3 with anti-PD-1

IMM Ann: TACTI-002 2nd line lung cancer data presented at 2022 WCLC

IMM Ann: Quarterly Activities/Appendix 4C Cash Flow Report

IMM Ann: Notification of cessation of securities - IMM

IMM Ann: Immutep granted Japanese Patent for IMP761

IMM Ann: TACTI-002 lung cancer data to be presented at 2022 WCLC

IMM Ann: Immutep Investor Update

IMM Ann: Webcast slides for 1st line NSCLC data from TACTI-002 trial

IMM Ann: Positive ORR in 1st line NSCLC from ph 2 TACTI-002 trial

IMM Ann: Immutep webcast for TACTI-002 data presented at ASCO 2022

IMM Ann: Immutep announces publication of ASCO 2022 abstracts

IMM Ann: Immutep Corporate Presentation

IMM Ann: Immutep to Present at Investor Conferences

IMM Ann: Leading Oncologists appointed to Clinical Advisory Board

IMM Ann: New & significant data from AIPAC phase 2b trial in MBC

IMM Ann: Quarterly Activities/Appendix 4C Cash Flow Report

IMM Ann: Immutep to announce new TACTI-002 data at ASCO 2022

IMM Ann: Change in substantial holding

IMM Ann: Efti with Keytruda shows encouraging activity in lung cancer

IMM Ann: Immutep announces publication of ELCC 2022 abstract

IMM Article: Immutep shares surge 8pc on FDA validation of its immune checkpoint

IMM Ann: Immutep to present Phase IIb breast cancer data at ESMO 2022

IMM Ann: Japanese patent granted for LAG-3 antibody LAG525

IMM Ann: Change in substantial holding

IMM Ann: Application for quotation of securities - IMM

IMM Ann: Immutep receives FDA feedback for Efti development in MBC

IMM Article: Why Immutep is Lucy Turnbull’s only ASX-listed company board role

IMM Ann: Initial Director's Interest Notice - Lucy Turnbull

IMM Ann: Proposed issue of securities - IMM

IMM Ann: Appointment of Non-Executive Director

IMM Ann: Immutep to Present at Healthcare Investor Conferences

IMM Ann: Half Yearly Report and Accounts

IMM Ann: Immutep to present new data from TACTI-002 at ELCC 2022

IMM Ann: Immutep Investor Update

IMM Ann: Australian Patent Granted for Efti with PD-1 Inhibitors

IMM Ann: Change in substantial holding

IMM Ann: Death of Director Grant Chamberlain

IMM Ann: Immutep to present at February Investor Conferences

IMM Ann: Immutep Quarterly Activities Report and Appendix 4C

IMM Ann: Change in substantial holding

IMM Ann: Immutep Advances IMP761 Manufacturing

IMM Ann: Change of Registered Office Address

IMM Ann: Amended Constitution

IMM Ann: Change in substantial holding

IMM Ann: Notification regarding unquoted securities - IMM

IMM Ann: Good safety reported from 1st five patients in INSIGHT-003

IMM Ann: Change of Director's Interest Notice - Dr. Howard

IMM Ann: Change of Director's Interest Notice - Mr Voigt

Register to track IMM and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMU
MSB
OPT
PAR
PYC
RAC
TLX